Viewing Asia as merely a "nice-to-have" is a critical strategic error. The imperative is not necessarily to invest, but to become deeply educated on the region's capabilities and competitive landscape. A decision to disengage is only valid if it's an informed one, made after sufficient study and consideration.
A new "Holdco" business model is emerging where Chinese firms act as holding companies. Instead of focusing on one or two internal assets, they leverage their region's discovery and development efficiency to build and accelerate a diverse portfolio of assets sourced from both within China and around the world.
The most significant shift isn't just Asia's rising share of the global drug pipeline (43%), but its contribution to its growth. A staggering 85% of the net new growth in innovative drug pipelines in 2024 originated from Asia, signaling a fundamental change in the global R&D landscape.
Instead of traditional regional HQs, firms should adopt a "capability-first" model. This involves strategically placing functions where excellence exists: basic science in Japan, clinical scale in China, and biologics in Korea. This creates a more efficient, interconnected global R&D engine, breaking from geography-based silos.
Beyond sheer scale, China's innovation leads in complex, next-generation drug modalities like ADCs and bispecifics. Chinese biotechs now account for roughly one-third of the global Phase 1 and 2 pipelines for these advanced therapies, indicating a shift from iteration on established targets to leadership in new technology platforms.
To bridge its translational research gap, Japan’s Agency of Medical Research and Development offers a unique fund. For qualified startups, it matches every dollar of venture capital investment with two dollars of non-dilutive government funding, providing crucial capital to advance early-stage assets without giving up equity.